Oral News and Research

RSS

Adeona reports $3,164,512 net revenue for 2010

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, reported its financial results for the year ended December 31, 2010, as well as updates since the beginning of the 4th quarter.

31 Mar 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

CEL-SCI Corporation announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in Israel.

31 Mar 2011

MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Montelukast Sodium Oral Soluble Film (OSF) under a 505(b)(2) pathway.

30 Mar 2011

Dr. Reddy’s acquires GSK's US penicillin facility and products

Dr. Reddy's Laboratories today announced the completion of the acquisition of GlaxoSmithKline's United States oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on Nov 23, 2010.

30 Mar 2011

New study: Periodontal therapy can help reduce medical costs for patients with diabetes

The results from a new CIGNA study support that there is a potential association between treated periodontal disease and reduced medical costs for patients with diabetes.

30 Mar 2011

Health law policy details continue to grab attention, headlines

Health law costs, accountable care organizations, the individual mandate and even the latest in proceedings surrounding Virginia's health law challenge are all in today's news.

30 Mar 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

Roundup: Ariz. may restore transplant coverage; Fla. faces class action suit over disabled waiting list

Kentucky health officials are considering restrictions on the number of cancer-fighting drugs Medicaid patients may receive without prior approval, a move designed to contain costs in the health care program for the poor and disabled. The possibility of creating a non-preferred list of oral oncology drugs — pills that replace intravenous chemotherapy drugs — that Medicaid won't pay for without prior approval has raised questions from patient advocates and those who treat cancer patients.

30 Mar 2011

Oral antioxidant formulation before medical imaging may minimize cell damage

A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Interventional radiologists have completed the first human randomized controlled trial of therapeutic renal denervation or RDN—a procedure that uses a catheter-based probe inserted into the renal artery that emits high-frequency energy to deactivate the nerves near the kidneys that are linked to high blood pressure.

29 Mar 2011

Keryx KRX-0401 trial data against colorectal cancer, multiple myeloma to be presented at AACR

Keryx Biopharmaceuticals, Inc. today announced that two abstracts on KRX-0401 will be presented at the upcoming 102nd annual meeting of the American Association for Cancer Research to be held in Orlando, Florida, from April 2-6, 2011.

29 Mar 2011

Lotus fiscal year revenue increases 28.7% to $72.7 million for 2010

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2010.

29 Mar 2011

Chembio develops DPP assay for rapid detection of HIV and HEP B/C

A kidney recipient in a New York City hospital recently contracted HIV from the transplanted organ, which came from a living donor, according to the New York State Department of Health. Although an initial screening had been performed on the donor, he or she apparently had unsafe sex after the test but before donating the kidney.

28 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

Research: Written action plan with prescriptions can improve asthma control in children

It sounds unbelievably simple but it's true - a written action plan for asthma treatment, attached to the drug prescription, improves asthma control in children. "Acute care visits for asthma often signal a management failure," said Dr. Francine Ducharme, of the University of Montreal's Department of Pediatrics and the Sainte-Justine University Hospital Centre.

28 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

Multi-disciplinary collaboration proposes intravenous vitamin C for treatment of cancer

The Riordan Clinic announced today publication in the Journal of Translational Medicine results of a collaboration between oncologists, alternative medicine practitioners, and basic researchers, which proposes a new use of intravenous vitamin C for treatment of cancer.

25 Mar 2011

Oral News and Research

Adeona reports $3,164,512 net revenue for 2010

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF

Dr. Reddy’s acquires GSK's US penicillin facility and products

New study: Periodontal therapy can help reduce medical costs for patients with diabetes

Health law policy details continue to grab attention, headlines

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Positive results from Vertex VX-770 Phase 3 trial against CF

Roundup: Ariz. may restore transplant coverage; Fla. faces class action suit over disabled waiting list

Oral antioxidant formulation before medical imaging may minimize cell damage

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Keryx KRX-0401 trial data against colorectal cancer, multiple myeloma to be presented at AACR

Lotus fiscal year revenue increases 28.7% to $72.7 million for 2010

Chembio develops DPP assay for rapid detection of HIV and HEP B/C

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Research: Written action plan with prescriptions can improve asthma control in children

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Multi-disciplinary collaboration proposes intravenous vitamin C for treatment of cancer

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News